MedTrace Logo

Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease

NCT03011476 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-03-07

No results posted yet for this study

Summary

Cholinergic deficiency in the brain can be related to gait and balance problems in Parkinson disease (PD). Recent clinical trials suggested a beneficial role of acetylcholinesterase inhibitors (AchEI) on gait in PD. In this study, the investigators are planning to study the influence of AchEI on a brain network for gait and balance in PD. As gait problem is prominent in postural instability and gait disturbance (PIGD) subtype, this study will focus on the patients with PIGD phenotype.

Conditions

  • Parkinson Disease

Interventions

DRUG

Donepezil

1. Start with 5 mg/day for 4 weeks 2. Increased to 10 mg/day for 8 weeks

DRUG

Placebos

1. Start with 5 mg/day for 4 weeks 2. Increased to 10 mg/day for 8 weeks

Sponsors & Collaborators

  • Kyung Hee University Hospital

    lead OTHER

Principal Investigators

  • Tae-Beom Ahn, MD, PhD · Kyung Hee University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-11
Primary Completion
2018-10-30
Completion
2018-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03011476 on ClinicalTrials.gov